163 related articles for article (PubMed ID: 1967317)
41. Identification and pharmacological characterization of a series of new 1H-4-substituted-imidazoyl histamine H3 receptor ligands.
Yates SL; Phillips JG; Gregory R; Pawlowski GP; Fadnis L; Khan MA; Ali SM; Tedford CE
J Pharmacol Exp Ther; 1999 May; 289(2):1151-9. PubMed ID: 10215699
[TBL] [Abstract][Full Text] [Related]
42. Therapeutic approach of histamine H3 receptors in obesity.
Masaki T; Yoshimatsu H
Recent Pat CNS Drug Discov; 2007 Nov; 2(3):238-40. PubMed ID: 18221234
[TBL] [Abstract][Full Text] [Related]
43. [Histamine and gastric acid secretion].
Gutiérrez Cabano CA
Acta Gastroenterol Latinoam; 1980; 10(1):77-84. PubMed ID: 6159765
[TBL] [Abstract][Full Text] [Related]
44. Histamine H3-receptor isoforms.
Bakker RA
Inflamm Res; 2004 Oct; 53(10):509-16. PubMed ID: 15597144
[TBL] [Abstract][Full Text] [Related]
45. Novel histamine H4 receptor ligands and their potential therapeutic applications: an update.
Kiss R; Keseru GM
Expert Opin Ther Pat; 2014 Nov; 24(11):1185-97. PubMed ID: 25219452
[TBL] [Abstract][Full Text] [Related]
46. The histamine H4 receptor and potential therapeutic uses for H4 ligands.
Jablonowski JA; Carruthers NI; Thurmond RL
Mini Rev Med Chem; 2004 Nov; 4(9):993-1000. PubMed ID: 15544559
[TBL] [Abstract][Full Text] [Related]
47. Pharmacological characterization of H3 receptor antagonists with imidazole, thioimidazole and thioimidazoline polar groups in the side chain.
Barocelli E; Ballabeni V; Chiavarini M; Bertoni S; Mor M; Plazzi PV; Bordi F; Impicciatore M
Inflamm Res; 2000 Apr; 49 Suppl 1():S62-3. PubMed ID: 10864424
[No Abstract] [Full Text] [Related]
48. Non-imidazole histamine H3 ligands. Part III. New 4-n-propylpiperazines as non-imidazole histamine H3-antagonists.
Walczyński K; Zuiderveld OP; Timmerman H
Eur J Med Chem; 2005 Jan; 40(1):15-23. PubMed ID: 15642406
[TBL] [Abstract][Full Text] [Related]
49. The histamine H3 receptor as a therapeutic drug target for CNS disorders.
Gemkow MJ; Davenport AJ; Harich S; Ellenbroek BA; Cesura A; Hallett D
Drug Discov Today; 2009 May; 14(9-10):509-15. PubMed ID: 19429511
[TBL] [Abstract][Full Text] [Related]
50. Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H3 receptor antagonist.
Esbenshade TA; Fox GB; Krueger KM; Baranowski JL; Miller TR; Kang CH; Denny LI; Witte DG; Yao BB; Pan JB; Faghih R; Bennani YL; Williams M; Hancock AA
Biochem Pharmacol; 2004 Sep; 68(5):933-45. PubMed ID: 15294456
[TBL] [Abstract][Full Text] [Related]
51. Binding of histamine H3-receptor antagonists to hematopoietic progenitor cells. Evidence for a histamine transporter unrelated to histamine H3 receptors.
Corbel S; Traiffort E; Stark H; Schunack W; Dy M
FEBS Lett; 1997 Mar; 404(2-3):289-93. PubMed ID: 9119081
[TBL] [Abstract][Full Text] [Related]
52. Stereoselectivity of the histamine H3-presynaptic autoreceptor.
Arrang JM; Schwartz JC; Schunack W
Eur J Pharmacol; 1985 Oct; 117(1):109-14. PubMed ID: 2417862
[TBL] [Abstract][Full Text] [Related]
53. Novel histamine H3 receptor antagonists based on the 4-[(1H-imidazol-4-yl)methyl]piperidine scaffold.
Vaccaro WD; Sher R; Berlin M; Shih NY; Aslanian R; Schwerdt JH; McCormick KD; Piwinski JJ; West RE; Anthes JC; Williams SM; Wu RL; She HS; Rivelli MA; Mutter JC; Corboz MR; Hey JA; Favreau L
Bioorg Med Chem Lett; 2006 Jan; 16(2):395-9. PubMed ID: 16246552
[TBL] [Abstract][Full Text] [Related]
54. Piperidine-containing histamine H3-receptor antagonists of the carbamate series: variation of the spacer length.
Łazewska D; Kieć-Kononowicz K; Pertz HH; Stark H; Schunack W; Elz S
Pharmazie; 2001 Dec; 56(12):927-32. PubMed ID: 11802653
[TBL] [Abstract][Full Text] [Related]
55. Histamine and histamine H1- and H2-receptor antagonists in acute inflammation.
Owen DA; Woodward DF
Biochem Soc Trans; 1980 Feb; 8(1):150-5. PubMed ID: 6102933
[No Abstract] [Full Text] [Related]
56. Piperidine-containing histamine H3 receptor antagonists of the carbamate series: the influence of the additional ether functionality.
Łazewska D; Kieć-Kononowicz K; Pertz HH; Elz S; Stark H; Schunack W
Pharmazie; 2002 Dec; 57(12):791-5. PubMed ID: 12561236
[TBL] [Abstract][Full Text] [Related]
57. Histamine H4 receptor antagonists: the new antihistamines?
Fung-Leung WP; Thurmond RL; Ling P; Karlsson L
Curr Opin Investig Drugs; 2004 Nov; 5(11):1174-83. PubMed ID: 15573868
[TBL] [Abstract][Full Text] [Related]
58. Histamine H3 receptor ligands break ground in a remarkable plethora of therapeutic areas.
Wijtmans M; Leurs R; de Esch I
Expert Opin Investig Drugs; 2007 Jul; 16(7):967-85. PubMed ID: 17594183
[TBL] [Abstract][Full Text] [Related]
59. Genetic and pharmacological aspects of histamine H3 receptor heterogeneity.
Hancock AA; Esbenshade TA; Krueger KM; Yao BB
Life Sci; 2003 Oct; 73(24):3043-72. PubMed ID: 14550847
[TBL] [Abstract][Full Text] [Related]
60. Further evidence for the role of histamine H3, but not H1, H2 or H4, receptors in immepip-induced inhibition of the rat cardioaccelerator sympathetic outflow.
Pinacho-García M; Marichal-Cancino BA; Villalón CM
Eur J Pharmacol; 2016 Feb; 773():85-92. PubMed ID: 26826593
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
